1.52
-2.56%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AIM Vaccine Co
Its shares trade on HKEX under the ticker 6660.HK. It has been listed since 6 October 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.36bn and a net loss of CN¥786.5m. At that date it held total assets of CN¥7.62bn and shareholders' equity of CN¥3.21bn.
AIM Vaccine Co., Ltd. engages in biological vaccine technology development, technology transfer, and technical services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-10-06. The firm's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The firm's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The firm's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The firm principally conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Oct 2022
- Employees
- 1,576
- Website
- aimbio.com ↗
Leadership
Pay as last reported
- Mr. Yan ZhouExecutive Chairman of the Board, Chief Executive OfficerHK$898.8m
- Mr. Xin ZhouExecutive President, Executive Director, since 2013HK$96,000
- Mr. Wen GuanExecutive Co-President , Executive Vice Chairman of the Board, since 2024HK$1.2m
- Mr. Shaojun JiaPresident, since 2017HK$1.2m
- Ms. Lixin NiuChief Financial Officer
- Ms. Ling LiuChief Investment Officer, Joint Company Secretary, since 2022
- Mr. Zhenyu LinChief Marketing Officer
- Mr. Jie ZhouExecutive Director, since 2015HK$96,000
- Ms. Li MengChief Quality Officer
- Mr. Fan ZhangChief Research Officer
- Ms. Wenjuan ZhouChief Public Affairs Officer
- Ms. Pui Kiu WongJoint Company Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AIM Vaccine Co Ltd's recombinant hepatitis B vaccine is a key product in the domestic market.
- The company's inactivated hepatitis A vaccine is widely used for hepatitis A treatment.
- AIM Vaccine Co Ltd's mRNA COVID-19 vaccine candidate shows promising development potential.
Weaknesses
- The firm's mumps vaccine has limited market presence compared to competitors.
- AIM Vaccine Co Ltd's inactivated hemorrhagic fever vaccine faces regional demand constraints.
- The company's MPSV4 vaccine lacks significant international distribution channels.
Opportunities
- The domestic market offers growth potential for AIM Vaccine Co Ltd's PCV13 vaccine candidate.
- Expanding the use of AIM Vaccine Co Ltd's PPSV23 vaccine in domestic healthcare systems.
- Increasing demand for AIM Vaccine Co Ltd's MCV4 vaccine in domestic public health programs.
Threats
- The domestic market's reliance on AIM Vaccine Co Ltd's human rabies vaccine creates supply chain risks.
- Competition from other domestic vaccine producers for AIM Vaccine Co Ltd's inactivated hepatitis A vaccine.
- Regulatory changes could impact AIM Vaccine Co Ltd's broad-spectrum COVID-19 vaccine development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.